AI · SEMICONDUCTOR · FACT CHECK
SKD WIREMostly True
SK Bioscience has introduced AI into its influenza vaccine manufacturing process, with plans to extend the technology into research and development and quality management, according to material presented by company officials at an industry summit.
SK Bioscience announced that it has adopted AI technology in the production of its influenza vaccines, according to a company press release. The company presented the initiative at the ABDD Summit, where Lee Yong, a team leader at SK Bioscience, outlined how AI is being integrated into manufacturing operations.
The disclosure was accompanied by official images from the company showing the team leader's presentation at the summit, which SK Bioscience attached to its press release.
Beyond production, SK Bioscience intends to broaden its use of AI into research and development as well as quality management, per the company's announcement. The company did not disclose specific timelines or technical details for these planned applications.
The move reflects a growing trend among biopharmaceutical manufacturers of applying AI tools across the vaccine value chain, from process optimization in production lines to post-manufacturing quality assurance.
SK Bioscience, a major South Korean vaccine producer, has positioned manufacturing excellence as a core strength, supplying influenza vaccines to both domestic and international markets. The introduction of AI into production signals the company's effort to modernize its manufacturing base while building capabilities that could support faster development cycles and more rigorous quality standards.
The company has not yet provided detailed figures on cost savings, efficiency gains, or investment amounts related to the AI deployment.
The claim that SK Bioscience has adopted AI in flu vaccine production with plans to expand into R&D and quality management aligns with the company's official announcements, making the claim Mostly True.